GenCore version 5.1.6

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 22, 2003, 14:07:07 ; Search time 104 Seconds
(without alignments)
4740.430 Million cell updates/sec

Title: US-09-745-506-74
Perfect score: 506
Sequence: 1 GTGATTGTTATCTTGGTGCT.....TCTGTTTACTTAACATCAA 1553

Scoring table: OLIGO
Xgapop 60.0 , Xgapext 60.0
Ygapop 60.0 , Ygapext 60.0
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 1107863 seqs, 158726573 residues

Word size: 1

Total number of hits satisfying chosen parameters: 2062474

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Command line parameters:
-MODEL=frame+_n2p.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool/US09745506/runat_22082003_132736_11166/app_query.fasta_1.1735
-DB=A_Geneseq_19Jun03 -QFMT=fastan -SUFFIX=n2poli.rag -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=oligo -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR_SCORE=quality -THR_MIN=1 -ALIGN=15 -MODE=LOCAL
-OUTFMT=pto -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US09745506_@CGN_1_1_137_@runat_22082003_132736_11166 -NCPU=6 -ICPU=3
-NO_MMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=60 -XGAPEXT=60 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=60 -YGAPEXT=60 -DELOP=6 -DELEXT=7

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		369	72.9	383	22	AAM88085	Human immune/haema
2		350	69.2	350	22	AAG81361	Human AFP protein
3		350	69.2	350	22	AAB94573	Human protein sequ
4		315	62.3	377	22	AAU27744	Human full-length
5		268	53.0	351	22	AAB60663	Human gene express
6		211	41.7	247	23	ABB08182	Human protein kina
7		102	20.2	110	22	ABG20985	Novel human diagno
8		68	13.4	68	22	ABG52473	Human liver peptid
9		68	13.4	68	22	ABB32385	Peptide #5036 enco
10		68	13.4	68	22	ABB37667	Peptide #5173 enco
11		68	13.4	68	22	AAM58295	Human brain expres
12		68	13.4	68	22	AAM18609	Peptide #5043 enco
13		68	13.4	68	22	AAM06178	Peptide #4860 enco
14		49	9.7	79	22	AAU21467	Human novel foetal
15		43	8.5	146	22	AAU27916	Human contig polyp
16		38	7.5	70	22	ABG20982	Novel human diagno
17		30	5.9	58	22	AAM90790	Human immune/haema
18		25	4.9	74	22	ABG20984	Novel human diagno
19	c	22	4.4	22	22	ABG20983	Novel human diagno
20		15	3.0	15	23	ABB08183	Human protein kina
21		10	2.0	360	22	AAG82528	S. epidermidis ope
22		10	2.0	367	23	ABP38833	Staphylococcus epi
23		9	1.8	334	23	ABP66109	Bifidobacterium lo
24		8	1.6	10	22	AAG95515	Human complementar
25	c	8	1.6	52	22	AAU65449	Propionibacterium
26		8	1.6	64	22	AAU21906	Human cardiovascul
27	c	8	1.6	96	23	ABG70062	Human prey protein
28	c	8	1.6	108	22	AAU66453	Propionibacterium
29		8	1.6	108	22	AAG92483	C glutamicum prote
30		8	1.6	161	22	AAU63960	Propionibacterium
31		8	1.6	179	12	AAR10310	Ovary tissue trans
32	c	8	1.6	218	22	AAU47094	Propionibacterium
33	c	8	1.6	299	22	AAU24644	Human olfactory re
34	c	8	1.6	299	22	AAG71682	Human olfactory re
35	c	8	1.6	299	23	ABG76794	Human G-protein co
36	c	8	1.6	299	23	AAU95727	Human olfactory an
37	c	8	1.6	299	23	AAU85264	G-coupled olfactor
38		8	1.6	345	23	AAE13351	Human TSTP protein
39	c	8	1.6	355	23	ABG91505	Purine/pyrimidine
40	c	8	1.6	355	24	ABP99273	Orthosomycin biosy
41	c	8	1.6	355	24	ABP76704	Streptomyces virid
42		8	1.6	367	19	AAW69999	Rodent chemokine r
43		8	1.6	368	19	AAW54371	Human IP-10/Mig re
44		8	1.6	368	21	AAY90614	Human G protein-co
45		8	1.6	368	21	AAY90648	Human mutant G pro

ALIGNMENTS

RESULT 1
AAM88085
ID AAM88085 standard; Protein; 383 AA.
XX
AC AAM88085;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:15678.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.

XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK60866.

```
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and
PT   metastasis -
XX
PS   Claim 11; SEQ ID NO 15678; 3071pp + Sequence Listing; English.
XX
CC   AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence   383 AA;

Alignment Scores:
Pred. No.:              0           Length:          383
Score:                  369.00      Matches:         369
Percent Similarity:     100.00%     Conservative:    0
Best Local Similarity:  100.00%     Mismatches:      0
Query Match:            72.92%      Indels:          0
DB:                     22          Gaps:            0

US-09-745-506-74 (1-1553) x AAM88085 (1-383)

Qy        188 GTCCCCACGACAGTCCGGTTTGTAGATTCCCTGATCTGCAATTCTTCCCGTTCCTTCATG 247
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         15 ValProThrThrValArgPheValAspSerLeuIleCysAsnSerSerArgSerPheMet 34

Qy        248 GATTTGAAGGCTCTCCTTTCTTCCTTGAATGACTTTGCATCCCTCTCGTTTGCTGAGAGT 307
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         35 AspLeuLysAlaLeuLeuSerSerLeuAsnAspPheAlaSerLeuSerPheAlaGluSer 54

Qy        308 TGGGACAATGTTGGATTACTGGTGGAACCAAGCCCACCACATACTGTAAATACACTCTTC 367
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         55 TrpAspAsnValGlyLeuLeuValGluProSerProProHisThrValAsnThrLeuPhe 74

Qy        368 CTGACCAATGACCTGACTGAGGAAGTGATGGAGGAGGTGCTGCAAAAGAAGGCAGACCTC 427
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         75 LeuThrAsnAspLeuThrGluGluValMetGluGluValLeuGlnLysLysAlaAspLeu 94

Qy        428 ATTCTCTCCTACCATCCGCCTATCTTCCGACCCATGAAGCGCATAACCTGGAACACATGG 487
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         95 IleLeuSerTyrHisProProIlePheArgProMetLysArgIleThrTrpAsnThrTrp 114

Qy        488 AAGGAGCGCCTGGTGATCCGGGCTCTGGAGAACAGAGTCGGTATCTACTCTCCTCATACA 547
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        115 LysGluArgLeuValIleArgAlaLeuGluAsnArgValGlyIleTyrSerProHisThr 134

Qy        548 GCCTATGATGCTGCGCCCCCAGGGCGTCAACAACTGGTTGGCTAAAGGGCTTGGAGCTTGT 607
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        135 AlaTyrAspAlaAlaProGlnGlyValAsnAsnTrpLeuAlaLysGlyLeuGlyAlaCys 154

Qy        608 ACCTCCAGGCCCATACATCCTTCCAAAGCTCCCAACTACCCTACAGAGGGAAACCACCGA 667
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        155 ThrSerArgProIleHisProSerLysAlaProAsnTyrProThrGluGlyAsnHisArg 174

Qy        668 GTAGAATTCAACGTTAACTACACCCAAGACCTGGACAAAGTCATGTCTGCAGTGAAAGGA 727
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        175 ValGluPheAsnValAsnTyrThrGlnAspLeuAspLysValMetSerAlaValLysGly 194

Qy        728 ATTGACGGTGTTTCTGTCACTTCTTTTTCTGCTAGGACTGGTAATGAGGAACAAACACGG 787
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        195 IleAspGlyValSerValThrSerPheSerAlaArgThrGlyAsnGluGluGlnThrArg 214

Qy        788 ATTAATCTGAATTGTACTCAGAAGGCTTTGATGCAGGTGGTAGATTTTCTTTCCCGGAAC 847
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        215 IleAsnLeuAsnCysThrGlnLysAlaLeuMetGlnValValAspPheLeuSerArgAsn 234

Qy        848 AAACAACTTTATCAGAAGACGGAAATTCTGTCACTGGAGAAGCCTTTGCTTCTACATACT 907
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        235 LysGlnLeuTyrGlnLysThrGluIleLeuSerLeuGluLysProLeuLeuLeuHisThr 254

Qy        908 GGAATGGGACGGTTATGCACACTGGATGAATCTGTCTCCCTGGCAACCATGATTGATCGA 967
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        255 GlyMetGlyArgLeuCysThrLeuAspGluSerValSerLeuAlaThrMetIleAspArg 274

Qy        968 ATAAAAAGACACCTAAAACTATCTCATATTCGCTTAGCCCTTGGGGTGGGGAGAACCTTA 1027
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        275 IleLysArgHisLeuLysLeuSerHisIleArgLeuAlaLeuGlyValGlyArgThrLeu 294

Qy       1028 GAGTCTCAAGTCAAAGTCGTGGCCCTGTGTGCTGGTTCTGGGAGCAGCGTTCTGCAGGGT 1087
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        295 GluSerGlnValLysValValAlaLeuCysAlaGlySerGlySerSerValLeuGlnGly 314

Qy       1088 GTTGAGGCTGACCTTTACCTCACAGGTGAGATGTCCCATCATGATACTTTGGATGCTGCT 1147
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        315 ValGluAlaAspLeuTyrLeuThrGlyGluMetSerHisHisAspThrLeuAspAlaAla 334

Qy       1148 TCCCAAGGAATAAATGTCATCCTCTGTGAACACAGCAACACTGAACGAGGCTTTCTTTCT 1207
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        335 SerGlnGlyIleAsnValIleLeuCysGluHisSerAsnThrGluArgGlyPheLeuSer 354

Qy       1208 GACCTTCGAGATATGCTGGATTCTCACTTGGAGAATAAGATAAATATTATCCTATCAGAG 1267
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        355 AspLeuArgAspMetLeuAspSerHisLeuGluAsnLysIleAsnIleIleLeuSerGlu 374

Qy       1268 ACTGACAGGGACCCTCTTCAGGTGGTA 1294
              ||||||||||||||||||||||||||
Db        375 ThrAspArgAspProLeuGlnValVal 383

RESULT 2
AAG81361
ID   AAG81361 standard; Protein; 350 AA.
XX
AC   AAG81361;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human AFP protein sequence SEQ ID NO:240.
XX
KW   Human; secreted protein; secretion; bacterial cell; fungal cell;
KW   eukaryotic cell; fusion protein; maltose binding protein;
KW   immunoglobulin constant region; polyhistidine tag.
XX
OS   Homo sapiens.
XX
PN   WO200129221-A2.
XX
PD   26-APR-2001.
XX
PF   20-OCT-2000; 2000WO-US29052.
XX
PR   20-OCT-1999;   99US-0160712.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Conklin DC,  Yee DP;
XX
DR   WPI; 2001-300340/31.
DR   N-PSDB; AAH52212.
XX
PT   Isolated polypeptide for directing secretion of proteins of interest
PT   from a host cell including, e.g. bacteria, includes contiguous amino
```

```
PT   acid residues of polypeptide with specified amino acids  -
XX
PS   Claim 1; Page 424-425; 617pp; English.
XX
CC   AAH52093 to AAH52303 encode the human secreted proteins given in AAG81242
CC   to AAG81453. The secreted proteins can be used for directing the
CC   secretion of proteins of interest from a host cell including bacteria,
CC   fungal cells, and cultured higher eukaryotic cells. The present invention
CC   also describes fusion proteins, where a secreted protein of the invention
CC   is operably linked via a peptide bond or peptide linker to a second
CC   protein selected from the group consisting of maltose binding protein,
CC   an immunoglobulin constant region, a polyhistidine tag and a peptide
CC   given in AAG81453.
XX
SQ   Sequence   350 AA;

Alignment Scores:
Pred. No.:              0           Length:         350
Score:                  350.00      Matches:        350
Percent Similarity:     100.00%     Conservative:   0
Best Local Similarity:  100.00%     Mismatches:     0
Query Match:            69.17%      Indels:         0
DB:                     22          Gaps:           0

US-09-745-506-74 (1-1553) x AAG81361 (1-350)

Qy       245 ATGGATTTGAAGGCTCTCCTTTCTTCCTTGAATGACTTTGCATCCCTCTCGTTTGCTGAG 304
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         1 MetAspLeuLysAlaLeuLeuSerSerLeuAsnAspPheAlaSerLeuSerPheAlaGlu  20

Qy       305 AGTTGGGACAATGTTGGATTACTGGTGGAACCAAGCCCACCACATACTGTAAATACACTC 364
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        21 SerTrpAspAsnValGlyLeuLeuValGluProSerProProHisThrValAsnThrLeu  40

Qy       365 TTCCTGACCAATGACCTGACTGAGGAAGTGATGGAGGAGGTGCTGCAAAAGAAGGCAGAC 424
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        41 PheLeuThrAsnAspLeuThrGluGluValMetGluGluValLeuGlnLysLysAlaAsp  60

Qy       425 CTCATTCTCTCCTACCATCCGCCTATCTTCCGACCCATGAAGCGCATAACCTGGAACACA 484
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        61 LeuIleLeuSerTyrHisProProIlePheArgProMetLysArgIleThrTrpAsnThr  80

Qy       485 TGGAAGGAGCGCCTGGTGATCCGGGCTCTGGAGAACAGAGTCGGTATCTACTCTCCTCAT 544
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        81 TrpLysGluArgLeuValIleArgAlaLeuGluAsnArgValGlyIleTyrSerProHis 100

Qy       545 ACAGCCTATGATGCTGCGCCCCAGGGCGTCAACAACTGGTTGGCTAAAGGGCTTGGAGCT 604
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       101 ThrAlaTyrAspAlaAlaProGlnGlyValAsnAsnTrpLeuAlaLysGlyLeuGlyAla 120

Qy       605 TGTACCTCCAGGCCCATACATCCTTCCAAAGCTCCCAACTACCCTACAGAGGGAAACCAC 664
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       121 CysThrSerArgProIleHisProSerLysAlaProAsnTyrProThrGluGlyAsnHis 140

Qy       665 CGAGTAGAATTCAACGTTAACTACACCCAAGACCTGGACAAAGTCATGTCTGCAGTGAAA 724
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       141 ArgValGluPheAsnValAsnTyrThrGlnAspLeuAspLysValMetSerAlaValLys 160

Qy       725 GGAATTGACGGTGTTTCTGTCACTTCTTTTTCTGCTAGGACTGGTAATGAGGAACAAACA 784
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       161 GlyIleAspGlyValSerValThrSerPheSerAlaArgThrGlyAsnGluGluGlnThr 180

Qy       785 CGGATTAATCTGAATTGTACTCAGAAGGCTTTGATGCAGGTGGTAGATTTTCTTTCCCGG 844
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       181 ArgIleAsnLeuAsnCysThrGlnLysAlaLeuMetGlnValValAspPheLeuSerArg 200

Qy       845 AACAAACAACTTTATCAGAAGACGGAAATTCTGTCACTGGAGAAGCCTTTGCTTCTACAT 904
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       201 AsnLysGlnLeuTyrGlnLysThrGluIleLeuSerLeuGluLysProLeuLeuLeuHis 220

Qy       905 ACTGGAATGGGACGGTTATGCACACTGGATGAATCTGTCTCCCTGGCAACCATGATTGAT 964
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       221 ThrGlyMetGlyArgLeuCysThrLeuAspGluSerValSerLeuAlaThrMetIleAsp 240

Qy       965 CGAATAAAAAGACACCTAAAACTATCTCATATTCGCTTAGCCCTTGGGGTGGGGAGAACC 1024
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       241 ArgIleLysArgHisLeuLysLeuSerHisIleArgLeuAlaLeuGlyValGlyArgThr 260

Qy      1025 TTAGAGTCTCAAGTCAAAGTCGTGGCCCTGTGTGCTGGTTCTGGGAGCAGCGTTCTGCAG 1084
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       261 LeuGluSerGlnValLysValValAlaLeuCysAlaGlySerGlySerSerValLeuGln 280

Qy      1085 GGTGTTGAGGCTGACCTTTACCTCACAGGTGAGATGTCCCATCATGATACTTTGGATGCT 1144
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       281 GlyValGluAlaAspLeuTyrLeuThrGlyGluMetSerHisHisAspThrLeuAspAla 300

Qy      1145 GCTTCCCAAGGAATAAATGTCATCCTCTGTGAACACAGCAACACTGAACGAGGCTTTCTT 1204
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       301 AlaSerGlnGlyIleAsnValIleLeuCysGluHisSerAsnThrGluArgGlyPheLeu 320

Qy      1205 TCTGACCTTCGAGATATGCTGGATTCTCACTTGGAGAATAAGATAAATATTATCCTATCA 1264
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       321 SerAspLeuArgAspMetLeuAspSerHisLeuGluAsnLysIleAsnIleIleLeuSer 340

Qy      1265 GAGACTGACAGGGACCCTCTTCAGGTGGTA 1294
             ||||||||||||||||||||||||||||||
Db       341 GluThrAspArgAspProLeuGlnValVal 350

RESULT 3
AAB94573
ID   AAB94573 standard; Protein; 350 AA.
XX
AC   AAB94573;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human protein sequence SEQ ID NO:15360.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 8; SEQ ID 15360; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
```

```
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence   350 AA;

Alignment Scores:
Pred. No.:                0          Length:          350
Score:                    350.00     Matches:         350
Percent Similarity:       100.00%    Conservative:    0
Best Local Similarity:    100.00%    Mismatches:      0
Query Match:              69.17%     Indels:          0
DB:                       22         Gaps:            0

US-09-745-506-74 (1-1553) x AAB94573 (1-350)

Qy        245 ATGGATTTGAAGGCTCTCCTTTCTTCCTTGAATGACTTTGCATCCCTCTCGTTTGCTGAG 304
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MetAspLeuLysAlaLeuLeuSerSerLeuAsnAspPheAlaSerLeuSerPheAlaGlu 20

Qy        305 AGTTGGGACAATGTTGGATTACTGGTGGAACCAAGCCCACCACATACTGTAAATACACTC 364
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         21 SerTrpAspAsnValGlyLeuLeuValGluProSerProProHisThrValAsnThrLeu 40

Qy        365 TTCCTGACCAATGACCTGACTGAGGAAGTGATGGAGGAGGTGCTGCAAAAGAAGGCAGAC 424
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         41 PheLeuThrAsnAspLeuThrGluGluValMetGluGluValLeuGlnLysLysAlaAsp 60

Qy        425 CTCATTCTCTCCTACCATCCGCCTATCTTCCGACCCATGAAGCGCATAACCTGGAACACA 484
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 LeuIleLeuSerTyrHisProProIlePheArgProMetLysArgIleThrTrpAsnThr 80

Qy        485 TGGAAGGAGCGCCTGGTGATCCGGGCTCTGGAGAACAGAGTCGGTATCTACTCTCCTCAT 544
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         81 TrpLysGluArgLeuValIleArgAlaLeuGluAsnArgValGlyIleTyrSerProHis 100

Qy        545 ACAGCCTATGATGCTGCGCCCCAGGGCGTCAACAACTGGTTGGCTAAAGGGCTTGGAGCT 604
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        101 ThrAlaTyrAspAlaAlaProGlnGlyValAsnAsnTrpLeuAlaLysGlyLeuGlyAla 120

Qy        605 TGTACCTCCAGGCCCATACATCCTTCCAAAGCTCCCAACTACCCTACAGAGGGAAACCAC 664
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CysThrSerArgProIleHisProSerLysAlaProAsnTyrProThrGluGlyAsnHis 140

Qy        665 CGAGTAGAATTCAACGTTAACTACACCCAAGACCTGGACAAAGTCATGTCTGCAGTGAAA 724
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        141 ArgValGluPheAsnValAsnTyrThrGlnAspLeuAspLysValMetSerAlaValLys 160

Qy        725 GGAATTGACGGTGTTTCTGTCACTTCTTTTTCTGCTAGGACTGGTAATGAGGAACAAACA 784
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        161 GlyIleAspGlyValSerValThrSerPheSerAlaArgThrGlyAsnGluGluGlnThr 180

Qy        785 CGGATTAATCTGAATTGTACTCAGAAGGCTTTGATGCAGGTGGTAGATTTTCTTTCCCGG 844
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 ArgIleAsnLeuAsnCysThrGlnLysAlaLeuMetGlnValValAspPheLeuSerArg 200

Qy        845 AACAAACAACTTTATCAGAAGACGGAAATTCTGTCACTGGAGAAGCCTTTGCTTCTACAT 904
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        201 AsnLysGlnLeuTyrGlnLysThrGluIleLeuSerLeuGluLysProLeuLeuLeuHis 220

Qy        905 ACTGGAATGGGACGGTTATGCACACTGGATGAATCTGTCTCCCTGGCAACCATGATTGAT 964
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        221 ThrGlyMetGlyArgLeuCysThrLeuAspGluSerValSerLeuAlaThrMetIleAsp 240

Qy        965 CGAATAAAAAGACACCTAAAACTATCTCATATTCGCTTAGCCCTTGGGGTGGGGAGAACC 1024
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 ArgIleLysArgHisLeuLysLeuSerHisIleArgLeuAlaLeuGlyValGlyArgThr 260

Qy       1025 TTAGAGTCTCAAGTCAAAGTCGTGGCCCTGTGTGCTGGTTCTGGGAGCAGCGTTCTGCAG 1084
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        261 LeuGluSerGlnValLysValValAlaLeuCysAlaGlySerGlySerSerValLeuGln 280

Qy       1085 GGTGTTGAGGCTGACCTTTACCTCACAGGTGAGATGTCCCATCATGATACTTTGGATGCT 1144
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        281 GlyValGluAlaAspLeuTyrLeuThrGlyGluMetSerHisHisAspThrLeuAspAla 300

Qy       1145 GCTTCCCAAGGAATAAATGTCATCCTCTGTGAACACAGCAACACTGAACGAGGCTTTCTT 1204
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 AlaSerGlnGlyIleAsnValIleLeuCysGluHisSerAsnThrGluArgGlyPheLeu 320

Qy       1205 TCTGACCTTCGAGATATGCTGGATTCTCACTTGGAGAATAAGATAAATATTATCCTATCA 1264
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        321 SerAspLeuArgAspMetLeuAspSerHisLeuGluAsnLysIleAsnIleIleLeuSer 340

Qy       1265 GAGACTGACAGGGACCCTCTTCAGGTGGTA 1294
              |||||||||||||||||||||||||||||
Db        341 GluThrAspArgAspProLeuGlnValVal 350

RESULT 4
AAU27744
ID   AAU27744 standard; Protein; 377 AA.
XX
AC   AAU27744;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human full-length polypeptide sequence #69.
XX
KW   Mammal; human; rhesus monkey; baker's yeast; fission yeast; Norway rat;
KW   mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukaemia;
KW   cancer; lymphoma; neuroblastoma; autoimmune disorder; cell proliferation;
KW   nervous system disorder; inflammatory disorder; cell differentiation;
KW   angiogenesis; stem cell growth factor; activin; inhibin; cartilage; burn;
KW   genetic disorder; bone regeneration; tendon; ligament; tissue repair;
KW   cytostatic; antirheumatic; antiarthritic; vulnerary; antiinflammatory;
KW   antibacterial; immunosuppressive; vasotropic; antiparkinsonian;
KW   neuroprotective; osteopathic; antidiabetic; antiasthmatic; antiallergic;
KW   immunostimulant; analgesic; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200164834-A2.
XX
PD   07-SEP-2001.
XX
PF   26-FEB-2001; 2001WO-US04926.
XX
PR   28-FEB-2000; 2000US-0515126.
PR   18-MAY-2000; 2000US-0577409.
PR   17-JUN-2000; 2000US-0597707.
PR   14-JUL-2000; 2000US-0616807.
PR   19-SEP-2000; 2000US-0664641.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Zhou P,  Asundi V,  Zhang J,  Zhao QA,  Ren F;
PI   Xue AJ,  Yang Y,  Wehrman T,  Wang J,  Ma Y,  Wang D,  Chen R,  Xu C;
PI   Drmanac R;
XX
DR   WPI; 2001-589862/66.
DR   N-PSDB; AAS44644.
XX
PT   Novel polypeptides and nucleic acids obtained from cDNA libraries
PT   prepared from various human tissues, for diagnosis, treatment of
PT   cancer, neurological, inflammatory disorders and for use in arrays for
```

```
PT   detection -
XX
PS   Claim 10; SEQ ID No 241; 153pp; English.
XX
CC   Sequences AAU27676-AAU28019 represent full-length polypeptides and
CC   contig polypeptides of the invention. The proteins and their associated
CC   DNA sequences are useful for the treatment, diagnosis and prevention of
CC   various types of disorder in a mammalian subject such as a human, dog,
CC   monkey, mouse, hamster or rat. The disorders include cancers such as
CC   leukaemia, lymphoma and neuroblastoma, autoimmune disorders such as
CC   multiple sclerosis, connective tissue disease, rheumatoid arthritis,
CC   diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
CC   disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
CC   chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
CC   Wernicke disease, inflammatory disorders such as nephritis, Crohn's
CC   disease, ischaemia-reperfusion injury, shock, sepsis and inflammatory
CC   bowel disease. The sequences exhibit activity relating to angiogenesis,
CC   cell proliferation, cell differentiation, stem cell growth factor,
CC   activin or inhibin. Therefore, they can be used to manipulate stem cells
CC   in culture to give rise to neuroepithelial cells that can be used to
CC   augment or replace cells damaged by illness, accidental damage or genetic
CC   disorders. The sequences may also be used for regeneration of bone,
CC   cartilage, tendons and ligaments and in tissue repair and burn healing.
CC   Note: Some sequences for this patent did not form part of the printed
CC   specification, but were obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   377 AA;

Alignment Scores:
Pred. No.:              3.92e-312      Length:          377
Score:                  315.00         Matches:         315
Percent Similarity:     100.00%        Conservative:    0
Best Local Similarity:  100.00%        Mismatches:      0
Query Match:            62.25%         Indels:          0
DB:                     22             Gaps:            0

US-09-745-506-74 (1-1553) x AAU27744 (1-377)

Qy        188 GTCCCCACGACAGTCCGGTTTGTAGATTCCCTGATCTGCAATTCTTCCCGTTCCTTCATG 247
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          9 ValProThrThrValArgPheValAspSerLeuIleCysAsnSerSerArgSerPheMet  28

Qy        248 GATTTGAAGGCTCTCCTTTCTTCCTTGAATGACTTTGCATCCCTCTCGTTTGCTGAGAGT 307
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         29 AspLeuLysAlaLeuLeuSerSerLeuAsnAspPheAlaSerLeuSerPheAlaGluSer  48

Qy        308 TGGGACAATGTTGGATTACTGGTGGAACCAAGCCCACCACATACTGTAAATACACTCTTC 367
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         49 TrpAspAsnValGlyLeuLeuValGluProSerProProHisThrValAsnThrLeuPhe  68

Qy        368 CTGACCAATGACCTGACTGAGGAAGTGATGGAGGAGGTGCTGCAAAAGAAGGCAGACCTC 427
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         69 LeuThrAsnAspLeuThrGluGluValMetGluGluValLeuGlnLysLysAlaAspLeu  88

Qy        428 ATTCTCTCCTACCATCCGCCTATCTTCCGACCCATGAAGCGCATAACCTGGAACACATGG 487
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         89 IleLeuSerTyrHisProProIlePheArgProMetLysArgIleThrTrpAsnThrTrp 108

Qy        488 AAGGAGCGCCTGGTGATCCGGGCTCTGGAGAACAGAGTCGGTATCTACTCTCCTCATACA 547
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        109 LysGluArgLeuValIleArgAlaLeuGluAsnArgValGlyIleTyrSerProHisThr 128

Qy        548 GCCTATGATGCTGCGCCCCCAGGGCGTCAACAACTGGTTGGCTAAAGGGCTTGGAGCTTGT 607
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        129 AlaTyrAspAlaAlaProGlnGlyValAsnAsnTrpLeuAlaLysGlyLeuGlyAlaCys 148

Qy        608 ACCTCCAGGCCCATACATCCTTCCAAAGCTCCCAACTACCCTACAGAGGGAAACCACCGA 667
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        149 ThrSerArgProIleHisProSerLysAlaProAsnTyrProThrGluGlyAsnHisArg 168

Qy        668 GTAGAATTCAACGTTAACTACACCCAAGACCTGGACAAAGTCATGTCTGCAGTGAAAGGA 727
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ValGluPheAsnValAsnTyrThrGlnAspLeuAspLysValMetSerAlaValLysGly 188

Qy        728 ATTGACGGTGTTTCTGTCACTTCTTTTTCTGCTAGGACTGGTAATGAGGAACAAACACGG 787
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        189 IleAspGlyValSerValThrSerPheSerAlaArgThrGlyAsnGluGluGlnThrArg 208

Qy        788 ATTAATCTGAATTGTACTCAGAAGGCTTTGATGCAGGTGGTAGATTTTCTTTCCCGGAAC 847
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        209 IleAsnLeuAsnCysThrGlnLysAlaLeuMetGlnValValAspPheLeuSerArgAsn 228

Qy        848 AAACAACTTTATCAGAAGACGGAAATTCTGTCACTGGAGAAGCCTTTGCTTCTACATACT 907
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 LysGlnLeuTyrGlnLysThrGluIleLeuSerLeuGluLysProLeuLeuLeuHisThr 248

Qy        908 GGAATGGGACGGTTATGCACACTGGATGAATCTGTCTCCCTGGCAACCATGATTGATCGA 967
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        249 GlyMetGlyArgLeuCysThrLeuAspGluSerValSerLeuAlaThrMetIleAspArg 268

Qy        968 ATAAAAAGACACCTAAAACTATCTCATATTCGCTTAGCCCTTGGGGTGGGGAGAACCTTA 1027
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        269 IleLysArgHisLeuLysLeuSerHisIleArgLeuAlaLeuGlyValGlyArgThrLeu 288

Qy       1028 GAGTCTCAAGTCAAAGTCGTGGCCCTGTGTGCTGGTTCTGGGAGCAGCGTTCTGCAGGGT 1087
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 GluSerGlnValLysValValAlaLeuCysAlaGlySerGlySerSerValLeuGlnGly 308

Qy       1088 GTTGAGGCTGACCTTTACCTCACAGGTGAGATGTCCCATCATGAT 1132
              |||||||||||||||||||||||||||||||||||||||||||||
Db        309 ValGluAlaAspLeuTyrLeuThrGlyGluMetSerHisHisAsp 323

RESULT 5
AAB60663
ID   AAB60663 standard; Protein; 351 AA.
XX
AC   AAB60663;
XX
DT   04-MAY-2001  (first entry)
XX
DE   Human gene expression regulatory factor-related protein hNIF3-s.
XX
KW   Human gene expression regulatory factor-related protein; hNIF3-s;
KW   NGG1-interacting factor; haemopoietic stem cell; preparation;
KW   detection.
XX
OS   Homo sapiens.
XX
PN   CN1272543-A.
XX
PD   08-NOV-2000.
XX
PF   11-APR-2000; 2000CN-0115369.
XX
PR   11-APR-2000; 2000CN-0115369.
XX
PA   (NANF-) NANFANG RES CENT STATE HUMAN GENE GROUP.
XX
PI   Li N,  Xiao H,  Liu F;
XX
DR   WPI; 2001-183596/19.
DR   N-PSDB; AAF59945.
XX
PT   Human gene expression regulatory factor related protein and its coded
PT   sequence -
XX
PS   Claim 4; Page 19-20; 20pp; Chinese.
XX
CC   The invention relates to a novel human gene expression regulatory
CC   factor-related protein, hNIF3-s (NGG1-interacting factor, AAB60663),
CC   and cDNA encoding it (AAF59945). hNIF3-s is expressed in haemopoietic
CC   stem cells. The invention also relates to the preparation of hNIF3-s
CC   proteins and nucleic acids, and the detection of hNIF3-s proteins and
CC   nucleic acids in a sample. The present sequence represents hNIF3-s.
XX
```

```
SQ   Sequence   351 AA;

Alignment Scores:
Pred. No.:              3.56e-264       Length:         351
Score:                  268.00          Matches:        268
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            52.96%          Indels:         0
DB:                     22              Gaps:           0

US-09-745-506-74 (1-1553) x AAB60663 (1-351)

Qy        491 GAGCGCCTGGTGATCCGGGCTCTGGAGAACAGAGTCGGTATCTACTCTCCTCATACAGCC 550
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         84 GluArgLeuValIleArgAlaLeuGluAsnArgValGlyIleTyrSerProHisThrAla 103

Qy        551 TATGATGCTGCGCCCCAGGGCGTCAACAACTGGTTGGCTAAAGGGCTTGGAGCTTGTACC 610
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        104 TyrAspAlaAlaProGlnGlyValAsnAsnTrpLeuAlaLysGlyLeuGlyAlaCysThr 123

Qy        611 TCCAGGCCCATACATCCTTCCAAAGCTCCCAACTACCCTACAGAGGGAAACCACCGAGTA 670
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        124 SerArgProIleHisProSerLysAlaProAsnTyrProThrGluGlyAsnHisArgVal 143

Qy        671 GAATTCAACGTTAACTACACCCAAGACCTGGACAAAGTCATGTCTGCAGTGAAAGGAATT 730
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        144 GluPheAsnValAsnTyrThrGlnAspLeuAspLysValMetSerAlaValLysGlyIle 163

Qy        731 GACGGTGTTTCTGTCACTTCTTTTTCTGCTAGGACTGGTAATGAGGAACAAACACGGATT 790
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        164 AspGlyValSerValThrSerPheSerAlaArgThrGlyAsnGluGluGlnThrArgIle 183

Qy        791 AATCTGAATTGTACTCAGAAGGCTTTGATGCAGGTGGTAGATTTTCTTTCCCGGAACAAA 850
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        184 AsnLeuAsnCysThrGlnLysAlaLeuMetGlnValValAspPheLeuSerArgAsnLys 203

Qy        851 CAACTTTATCAGAAGACGGAAATTCTGTCACTGGAGAAGCCTTTGCTTCTACATACTGGA 910
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        204 GlnLeuTyrGlnLysThrGluIleLeuSerLeuGluLysProLeuLeuLeuHisThrGly 223

Qy        911 ATGGGACGGTTATGCACACTGGATGAATCTGTCTCCCTGGCAACCATGATTGATCGAATA 970
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        224 MetGlyArgLeuCysThrLeuAspGluSerValSerLeuAlaThrMetIleAspArgIle 243

Qy        971 AAAAGACACCTAAAACTATCTCATATTCGCTTAGCCCTTGGGGTGGGGAGAACCTTAGAG 1030
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        244 LysArgHisLeuLysLeuSerHisIleArgLeuAlaLeuGlyValGlyArgThrLeuGlu 263

Qy       1031 TCTCAAGTCAAAGTCGTGGCCCTGTGTGCTGGTTCTGGGAGCAGCGTTCTGCAGGGTGTT 1090
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        264 SerGlnValLysValValAlaLeuCysAlaGlySerGlySerSerValLeuGlnGlyVal 283

Qy       1091 GAGGCTGACCTTTACCTCACAGGTGAGATGTCCCATCATGATACTTTGGATGCTGCTTCC 1150
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        284 GluAlaAspLeuTyrLeuThrGlyGluMetSerHisHisAspThrLeuAspAlaAlaSer 303

Qy       1151 CAAGGAATAAATGTCATCCTCTGTGAACACAGCAACACTGAACGAGGCTTTCTTTCTGAC 1210
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        304 GlnGlyIleAsnValIleLeuCysGluHisSerAsnThrGluArgGlyPheLeuSerAsp 323

Qy       1211 CTTCGAGATATGCTGGATTCTCACTTGGAGAATAAGATAAATATTATCCTATCAGAGACT 1270
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        324 LeuArgAspMetLeuAspSerHisLeuGluAsnLysIleAsnIleIleLeuSerGluThr 343

Qy       1271 GACAGGGACCCTCTTCAGGTGGTA 1294
              |||||||||||||||||||||||||
Db        344 AspArgAspProLeuGlnValVal 351

RESULT 6
ABB08182
ID   ABB08182 standard; Protein; 247 AA.
XX
AC   ABB08182;
XX
DT   23-SEP-2002  (first entry)
XX
DE   Human protein kinase C 27.17 polypeptide.
XX
KW   Human; protein kinase C 27.17; protein metabolism; enzyme.
XX
OS   Homo sapiens.
XX
PN   CN1333355-A.
XX
PD   30-JAN-2002.
XX
PF   07-JUL-2000; 2000CN-0117049.
XX
PR   07-JUL-2000; 2000CN-0117049.
XX
PA   (SHAN-) SHANGHAI BIODOOR GENE DEV CO LTD.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2002-305609/35.
DR   N-PSDB; ABL60919.
XX
PT   Human protein kinase C 27.17 polypeptide and its encoding
PT   polynucleotide, for treating e.g. protein metabolism disturbance -
XX
PS   Claim 1; Page 26-27 (disclosure); 33pp; Chinese.
XX
CC   The invention relates to a human protein kinase C 27.17 polypeptide and
CC   its encoding polynucleotide. The polypeptide can be expressed by standard
CC   DNA recombination. The polynucleotide, polypeptide and its antagonist are
CC   useful for treating e.g. protein metabolism disturbance. The present
CC   sequence represents the human protein kinase C 27.17 polypeptide.
XX
SQ   Sequence   247 AA;

Alignment Scores:
Pred. No.:              5.39e-206       Length:         247
Score:                  211.00          Matches:        211
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            41.70%          Indels:         0
DB:                     23              Gaps:           0

US-09-745-506-74 (1-1553) x ABB08182 (1-247)

Qy        662 CACCGAGTAGAATTCAACGTTAACTACACCCAAGACCTGGACAAAGTCATGTCTGCAGTG 721
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         37 HisArgValGluPheAsnValAsnTyrThrGlnAspLeuAspLysValMetSerAlaVal 56

Qy        722 AAAGGAATTGACGGTGTTTCTGTCACTTCTTTTTCTGCTAGGACTGGTAATGAGGAACAA 781
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         57 LysGlyIleAspGlyValSerValThrSerPheSerAlaArgThrGlyAsnGluGluGln 76

Qy        782 ACACGGATTAATCTGAATTGTACTCAGAAGGCTTTGATGCAGGTGGTAGATTTTCTTTCC 841
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         77 ThrArgIleAsnLeuAsnCysThrGlnLysAlaLeuMetGlnValValAspPheLeuSer 96

Qy        842 CGGAACAAACAACTTTATCAGAAGACGGAAATTCTGTCACTGGAGAAGCCTTTGCTTCTA 901
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         97 ArgAsnLysGlnLeuTyrGlnLysThrGluIleLeuSerLeuGluLysProLeuLeuLeu 116

Qy        902 CATACTGGAATGGGACGGTTATGCACACTGGATGAATCTGTCTCCCTGGCAACCATGATT 961
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        117 HisThrGlyMetGlyArgLeuCysThrLeuAspGluSerValSerLeuAlaThrMetIle 136

Qy        962 GATCGAATAAAAAAGACACCTAAAACTATCTCATATTCGCTTAGCCCTTGGGGTGGGGAGA 1021
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        137 AspArgIleLysArgHisLeuLysLeuSerHisIleArgLeuAlaLeuGlyValGlyArg 156

Qy       1022 ACCTTAGAGTCTCAAGTCAAAGTCGTGGCCCTGTGTGCTGGTTCTGGGAGCAGCGTTCTG 1081
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        157 ThrLeuGluSerGlnValLysValValAlaLeuCysAlaGlySerGlySerSerValLeu 176

Qy       1082 CAGGGTGTTGAGGCTGACCTTTACCTCACAGGTGAGATGTCCCATCATGATACTTTGGAT 1141
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        177 GlnGlyValGluAlaAspLeuTyrLeuThrGlyGluMetSerHisHisAspThrLeuAsp 196

Qy       1142 GCTGCTTCCCAAGGAATAAATGTCATCCTCTGTGAACACAGCAACACTGAACGAGGCTTT 1201
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        197 AlaAlaSerGlnGlyIleAsnValIleLeuCysGluHisSerAsnThrGluArgGlyPhe 216

Qy       1202 CTTTCTGACCTTCGAGATATGCTGGATTCTCACTTGGAGAATAAGATAAATATTATCCTA 1261
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        217 LeuSerAspLeuArgAspMetLeuAspSerHisLeuGluAsnLysIleAsnIleIleLeu 236

Qy       1262 TCAGAGACTGACAGGGACCCTCTTCAGGTGGTA 1294
              ||||||||||||||||||||||||||||||||
Db        237 SerGluThrAspArgAspProLeuGlnValVal 247
```

RESULT 7
ABG20985
ID ABG20985 standard; Protein; 110 AA.
XX
AC ABG20985;
XX
DT 18-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #20976.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS85172.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 51344; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 110 AA;

Alignment Scores:

Pred. No.:	1e-94	Length:	110
Score:	102.00	Matches:	102
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	20.16%	Indels:	0
DB:	22	Gaps:	0

US-09-745-506-74 (1-1553) x ABG20985 (1-110)

```
Qy        764 ACTGGTAATGAGGAACAAACACGGATTAATCTGAATTGTACTCAGAAGGCTTTGATGCAG 823
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          2 ThrGlyAsnGluGluGlnThrArgIleAsnLeuAsnCysThrGlnLysAlaLeuMetGln 21

Qy        824 GTGGTAGATTTTCTTTCCCGGAACAAACAACTTTATCAGAAGACGGAAATTCTGTCACTG 883
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 ValValAspPheLeuSerArgAsnLysGlnLeuTyrGlnLysThrGluIleLeuSerLeu 41

Qy        884 GAGAAGCCTTTGCTTCTACATACTGGAATGGGACGGTTATGCACACTGGATGAATCTGTC 943
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         42 GluLysProLeuLeuLeuHisThrGlyMetGlyArgLeuCysThrLeuAspGluSerVal 61

Qy        944 TCCCTGGCAACCATGATTGATCGAATAAAAAGACACCTAAAACTATCTCATATTCGCTTA 1003
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         62 SerLeuAlaThrMetIleAspArgIleLysArgHisLeuLysLeuSerHisIleArgLeu 81

Qy       1004 GCCCTTGGGGTGGGGAGAACCTTAGAGTCTCAAGTCAAAGTCGTGGCCCTGTGTGCTGGT 1063
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 AlaLeuGlyValGlyArgThrLeuGluSerGlnValLysValValAlaLeuCysAlaGly 101

Qy       1064 TCTGGG 1069
              ||||||
Db        102 SerGly 103
```

RESULT 8
ABG52473
ID ABG52473 standard; Peptide; 68 AA.
XX
AC ABG52473;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver peptide, SEQ ID No 31121.
XX
KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00664.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;

```
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analysing gene expression in human adult liver -
XX
PS   Claim 27; SEQ ID No 31121; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult
CC   liver. (I) may be used for predicting, measuring and displaying gene
CC   expression in samples derived from human adult liver. The genes
CC   identified may be involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which
CC   is associated with coronary heart disease. ABG47348-ABG59930 represent
CC   human liver single exon encoded peptides of the invention.
CC   Note: The sequence information for this patent does not appear in the
CC   printed specification but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

Alignment Scores:
Pred. No.:              5.29e-60      Length:         68
Score:                  68.00         Matches:        68
Percent Similarity:     100.00%       Conservative:   0
Best Local Similarity:  100.00%       Mismatches:     0
Query Match:            13.44%        Indels:         0
DB:                     22            Gaps:           0

US-09-745-506-74 (1-1553) x ABG52473 (1-68)

Qy        395 ATGGAGGAGGTGCTGCAAAAGAAGGCAGACCTCATTCTCTCCTACCATCCGCCTATCTTC 454
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MetGluGluValLeuGlnLysLysAlaAspLeuIleLeuSerTyrHisProProIlePhe 20

Qy        455 CGACCCATGAAGCGCATAACCTGGAACACATGGAAGGAGCGCCTGGTGATCCGGGCTCTG 514
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         21 ArgProMetLysArgIleThrTrpAsnThrTrpLysGluArgLeuValIleArgAlaLeu 40

Qy        515 GAGAACAGAGTCGGTATCTACTCTCCTCATACAGCCTATGATGCTGCGCCCCAGGGCGTC 574
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         41 GluAsnArgValGlyIleTyrSerProHisThrAlaTyrAspAlaAlaProGlnGlyVal 60

Qy        575 AACAACTGGTTGGCTAAAGGGCTT 598
              ||||||||||||||||||||||||
Db         61 AsnAsnTrpLeuAlaLysGlyLeu 68

RESULT 9
ABB32385
ID   ABB32385 standard; Peptide; 68 AA.
XX
AC   ABB32385;
XX
DT   01-FEB-2002  (first entry)
XX
DE   Peptide #5036 encoded by breast cell single exon nucleic acid probe.
XX
KW   Human; microarray; single exon probe; gene expression; breast;
KW   disease; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157271-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00662.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-496933/54.
XX
PT   New spatially-addressable set of single exon nucleic acid probes,
PT   useful for measuring gene expression in sample derived from human
PT   breast, comprises number of single exon nucleic acid probes  -
XX
PS   Claim 27; SEQ ID NO 15353; 327pp + sequence listing; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human breast and BT 474 cells. The method involves contacting
CC   the probes with a collection of detectably labelled nucleic acids
CC   derived from mRNA of human breast, and then measuring the label
CC   bound to each probe of the microarray. The probes are useful for
CC   verifying the expression of regions of genomic DNA predicted to
CC   encode proteins. They are useful for gene discovery, and for
CC   determining predisposition and/or prognosing breast disease. Gene
CC   expression analysis is useful for assessing the toxicity of chemical
CC   agents on cells. The microarray of this invention presents a far greater
CC   diversity of probes for measuring gene expression, with far less bias
CC   than expressed sequence tag microarrays. The method is suitable for
CC   rapid production of functional information from genomic sequence. The
CC   present sequence is a peptide encoded by a single exon nucleic acid
CC   probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

Alignment Scores:
Pred. No.:              5.29e-60      Length:         68
Score:                  68.00         Matches:        68
Percent Similarity:     100.00%       Conservative:   0
Best Local Similarity:  100.00%       Mismatches:     0
Query Match:            13.44%        Indels:         0
DB:                     22            Gaps:           0

US-09-745-506-74 (1-1553) x ABB32385 (1-68)

Qy        395 ATGGAGGAGGTGCTGCAAAAGAAGGCAGACCTCATTCTCTCCTACCATCCGCCTATCTTC 454
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MetGluGluValLeuGlnLysLysAlaAspLeuIleLeuSerTyrHisProProIlePhe 20

Qy        455 CGACCCATGAAGCGCATAACCTGGAACACATGGAAGGAGCGCCTGGTGATCCGGGCTCTG 514
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         21 ArgProMetLysArgIleThrTrpAsnThrTrpLysGluArgLeuValIleArgAlaLeu 40

Qy        515 GAGAACAGAGTCGGTATCTACTCTCCTCATACAGCCTATGATGCTGCGCCCCAGGGCGTC 574
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         41 GluAsnArgValGlyIleTyrSerProHisThrAlaTyrAspAlaAlaProGlnGlyVal 60

Qy        575 AACAACTGGTTGGCTAAAGGGCTT 598
              ||||||||||||||||||||||||
Db         61 AsnAsnTrpLeuAlaLysGlyLeu 68

RESULT 10
ABB37667
ID   ABB37667 standard; Peptide; 68 AA.
XX
AC   ABB37667;
XX
```

```
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #5173 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00669.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human fetal liver -
XX
PS   Claim 27; SEQ ID NO 30302; 639pp + sequence listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for
CC   measuring human gene expression in a sample derived from human foetal
CC   liver. The single exon nucleic acid probes may be used for predicting,
CC   measuring and displaying gene expression in samples derived from human
CC   fetal liver. The present sequence is a peptide encoded by a single exon
CC   nucleic acid probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

Alignment Scores:
Pred. No.:              5.29e-60      Length:         68
Score:                  68.00         Matches:        68
Percent Similarity:     100.00%       Conservative:   0
Best Local Similarity:  100.00%       Mismatches:     0
Query Match:            13.44%        Indels:         0
DB:                     22            Gaps:           0

US-09-745-506-74 (1-1553) x ABB37667 (1-68)

Qy        395 ATGGAGGAGGTGCTGCAAAAGAAGGCAGACCTCATTCTCTCCTACCATCCGCCTATCTTC 454
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MetGluGluValLeuGlnLysLysAlaAspLeuIleLeuSerTyrHisProProIlePhe 20

Qy        455 CGACCCATGAAGCGCATAACCTGGAACACATGGAAGGAGCGCCTGGTGATCCGGGCTCTG 514
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         21 ArgProMetLysArgIleThrTrpAsnThrTrpLysGluArgLeuValIleArgAlaLeu 40

Qy        515 GAGAACAGAGTCGGTATCTACTCTCCTCATACAGCCTATGATGCTGCGCCCCAGGGCGTC 574
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         41 GluAsnArgValGlyIleTyrSerProHisThrAlaTyrAspAlaAlaProGlnGlyVal 60

Qy        575 AACAACTGGTTGGCTAAAGGGCTT 598
              ||||||||||||||||||||||||
Db         61 AsnAsnTrpLeuAlaLysGlyLeu 68

RESULT 11
AAM58295
ID   AAM58295 standard; Protein; 68 AA.
XX
AC   AAM58295;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 30400.
XX
KW   Human; brain expressed exon; gene expression analysis; probe;
KW   microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW   epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00667.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains -
XX
PS   Example 4; SEQ ID NO: 30400; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention.
XX
SQ   Sequence   68 AA;

Alignment Scores:
Pred. No.:              5.29e-60      Length:         68
Score:                  68.00         Matches:        68
Percent Similarity:     100.00%       Conservative:   0
Best Local Similarity:  100.00%       Mismatches:     0
Query Match:            13.44%        Indels:         0
DB:                     22            Gaps:           0

US-09-745-506-74 (1-1553) x AAM58295 (1-68)

Qy        395 ATGGAGGAGGTGCTGCAAAAGAAGGCAGACCTCATTCTCTCCTACCATCCGCCTATCTTC 454
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MetGluGluValLeuGlnLysLysAlaAspLeuIleLeuSerTyrHisProProIlePhe 20

Qy        455 CGACCCATGAAGCGCATAACCTGGAACACATGGAAGGAGCGCCTGGTGATCCGGGCTCTG 514
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         21 ArgProMetLysArgIleThrTrpAsnThrTrpLysGluArgLeuValIleArgAlaLeu 40

Qy        515 GAGAACAGAGTCGGTATCTACTCTCCTCATACAGCCTATGATGCTGCGCCCCAGGGCGTC 574
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         41 GluAsnArgValGlyIleTyrSerProHisThrAlaTyrAspAlaAlaProGlnGlyVal 60

Qy        575 AACAACTGGTTGGCTAAAGGGCTT 598
              ||||||||||||||||||||||||
```

```
Db         61 AsnAsnTrpLeuAlaLysGlyLeu 68

RESULT 12
AAM18609
ID   AAM18609 standard; Protein; 68 AA.
XX
AC   AAM18609;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #5043 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00670.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human cervical epithelial cells -
XX
PS   Claim 27; SEQ ID No 23435; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

Alignment Scores:
Pred. No.:              5.29e-60      Length:         68
Score:                  68.00         Matches:        68
Percent Similarity:     100.00%       Conservative:   0
Best Local Similarity:  100.00%       Mismatches:     0
Query Match:            13.44%        Indels:         0
DB:                     22            Gaps:           0

US-09-745-506-74 (1-1553) x AAM18609 (1-68)

Qy        395 ATGGAGGAGGTGCTGCAAAAGAAGGCAGACCTCATTCTCTCCTACCATCCGCCTATCTTC 454
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MetGluGluValLeuGlnLysLysAlaAspLeuIleLeuSerTyrHisProProIlePhe 20

Qy        455 CGACCCATGAAGCGCATAACCTGGAACACATGGAAGGAGCGCCTGGTGATCCGGGCTCTG 514
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         21 ArgProMetLysArgIleThrTrpAsnThrTrpLysGluArgLeuValIleArgAlaLeu 40

Qy        515 GAGAACAGAGTCGGTATCTACTCTCCTCATACAGCCTATGATGCTGCGCCCCAGGGCGTC 574
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         41 GluAsnArgValGlyIleTyrSerProHisThrAlaTyrAspAlaAlaProGlnGlyVal 60

Qy        575 AACAACTGGTTGGCTAAAGGGCTT 598
              ||||||||||||||||||||||||
Db         61 AsnAsnTrpLeuAlaLysGlyLeu 68

RESULT 13
AAM06178
ID   AAM06178 standard; Protein; 68 AA.
XX
AC   AAM06178;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Peptide #4860 encoded by probe for measuring breast gene expression.
XX
KW   Probe; human; breast disease; breast cancer; development disorder;
KW   inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS   Homo sapiens.
XX
PN   WO200157270-A2.
XX
PD   09-AUG-2001.
XX
PF   29-JAN-2001; 2001WO-US00661.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression
PT   in a human breast -
XX
PS   Claim 27; SEQ ID No 14918; 322pp; English.
XX
CC   The present invention relates to novel single exon nucleic acid probes
CC   (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for measuring human gene expression in
CC   a human breast sample, where the probe hybridises at high stringency to a
CC   nucleic acid expressed in the human breast. The probes are useful for
CC   predicting, diagnosing, grading, staging, monitoring and prognosing
CC   diseases of the human breast, particularly those diseases with polygenic
CC   aetiology. The diseases include: breast cancer, disorders of development,
CC   inflammatory diseases of the breast, fibrocystic changes, proliferative
CC   breast disease and non-carcinoma tumours.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

Alignment Scores:
Pred. No.:              5.29e-60      Length:         68
Score:                  68.00         Matches:        68
Percent Similarity:     100.00%       Conservative:   0
Best Local Similarity:  100.00%       Mismatches:     0
Query Match:            13.44%        Indels:         0
DB:                     22            Gaps:           0
```

```
US-09-745-506-74 (1-1553) x AAM06178 (1-68)

Qy        395 ATGGAGGAGGTGCTGCAAAAGAAGGCAGACCTCATTCTCTCCTACCATCCGCCTATCTTC 454
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MetGluGluValLeuGlnLysLysAlaAspLeuIleLeuSerTyrHisProProIlePhe 20

Qy        455 CGACCCATGAAGCGCATAACCTGGAACACATGGAAGGAGCGCCTGGTGATCCGGGCTCTG 514
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         21 ArgProMetLysArgIleThrTrpAsnThrTrpLysGluArgLeuValIleArgAlaLeu 40

Qy        515 GAGAACAGAGTCGGTATCTACTCTCCTCATACAGCCTATGATGCTGCGCCCCAGGGCGTC 574
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         41 GluAsnArgValGlyIleTyrSerProHisThrAlaTyrAspAlaAlaProGlnGlyVal 60

Qy        575 AACAACTGGTTGGCTAAAGGGCTT 598
              ||||||||||||||||||||||||
Db         61 AsnAsnTrpLeuAlaLysGlyLeu 68
```

RESULT 14
AAU21467
ID AAU21467 standard; Protein; 79 AA.
XX
AC AAU21467;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human novel foetal antigen, SEQ ID NO 1711.
XX
KW Human; foetal tissue antigen; antiinflammatory; neuroprotective;
KW immunomodulator; cardiovascular; cytostatic; nephrothropic;
KW cardiovascular; autoimmune disease; rheumatoid arthritis;
KW hyperproliferative disorder; breast neoplasm; cancer;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; food additive.
XX
OS Homo sapiens.
XX
PN WO200155312-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01321.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.

PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488782/53.
DR N-PSDB; AAS34287.
XX
PT New polynucleotides and polypeptides for diagnosing, treating,
PT preventing or prognosing e.g. diseases or disorders of the nervous,
PT musculoskeletal, excretory, gastrointestinal, reproductive, and
PT respiratory systems -
XX
PS Claim 11; SEQ ID No 1711; 642pp; English.
XX
CC The invention relates to novel nucleic acids encoding novel human foetal
CC antigens. The nucleic acids and proteins are used to prevent, treat (e.g.
CC by gene therapy) or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They
CC are also used in diagnosing a pathological condition or susceptibility
CC to a pathological condition. The antibodies to the antigens can also
CC be used in alleviating symptoms associated with the disorders and in
CC diagnostic immunoassays e.g. radioimmunoassays or enzyme linked
CC immunosorbent assays (ELISA). Disorders which are diagnosed or treated
CC include autoimmune diseases e.g. rheumatoid arthritis,
CC hyperproliferative disorders e.g. neoplasms of the breast or liver,
CC cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders
CC e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.
CC Alzheimer's disease, infections caused by bacteria, viruses and fungi
CC and ocular disorders e.g. corneal infection. The polypeptides can also
CC be used to aid wound healing and epithelial cell proliferation, to
CC prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. Numerous
CC examples of diseases and disorders treated by the nucleic acids and
CC proteins are given in the specification. The present sequence

Alignment Scores:

Pred. No.:	1.25e-40	Length:	79
Score:	49.00	Matches:	49
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	9.68%	Indels:	0
DB:	22	Gaps:	0

US-09-745-506-74 (1-1553) x AAU21467 (1-79)

```
Qy        596 CTTGGAGCTTGTACCTCCAGGCCCATACATCCTTCCAAAGCTCCCAACTACCCTACAGAG 655
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         15 LeuGlyAlaCysThrSerArgProIleHisProSerLysAlaProAsnTyrProThrGlu 34

Qy        656 GGAAACCACCGAGTAGAATTCAACGTTAACTACACCCAAGACCTGGACAAAGTCATGTCT 715
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         35 GlyAsnHisArgValGluPheAsnValAsnTyrThrGlnAspLeuAspLysValMetSer 54

Qy        716 GCAGTGAAAGGAATTGACGGTGTTTCT 742
              |||||||||||||||||||||||||||
Db         55 AlaValLysGlyIleAspGlyValSer 63
```

RESULT 15
AAU27916
ID AAU27916 standard; Protein; 146 AA.
XX
AC AAU27916;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human contig polypeptide sequence #69.
XX
KW Mammal; human; rhesus monkey; baker's yeast; fission yeast; Norway rat;
KW mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukaemia;
KW cancer; lymphoma; neuroblastoma; autoimmune disorder; cell proliferation;
KW nervous system disorder; inflammatory disorder; cell differentiation;
KW angiogenesis; stem cell growth factor; activin; inhibin; cartilage; burn;
KW genetic disorder; bone regeneration; tendon; ligament; tissue repair;
KW cytostatic; antirheumatic; antiarthritic; vulnerary; antiinflammatory;
KW antibacterial; immunosuppressive; vasotropic; antiparkinsonian;
KW neuroprotective; osteopathic; antidiabetic; antiasthmatic; antiallergic;
KW immunostimulant; analgesic; gene therapy.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200164834-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US04926.
XX
PR 28-FEB-2000; 2000US-0515126.
PR 18-MAY-2000; 2000US-0577409.
PR 17-JUN-2000; 2000US-0597707.
PR 14-JUL-2000; 2000US-0616807.
PR 19-SEP-2000; 2000US-0664641.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
PI Xue AJ, Yang Y, Wehrman T, Wang J, Ma Y, Wang D, Chen R, Xu C;
PI Drmanac R;
XX
DR WPI; 2001-589862/66.
DR N-PSDB; AAS44816.
XX
PT Novel polypeptides and nucleic acids obtained from cDNA libraries
PT prepared from various human tissues, for diagnosis, treatment of
PT cancer, neurological, inflammatory disorders and for use in arrays for
PT detection -

XX
PS Claim 10; Page 132; 153pp; English.
XX
CC Sequences AAU27676-AAU28019 represent full-length polypeptides and
CC contig polypeptides of the invention. The proteins and their associated
CC DNA sequences are useful for the treatment, diagnosis and prevention of
CC various types of disorder in a mammalian subject such as a human, dog,
CC monkey, mouse, hamster or rat. The disorders include cancers such as
CC leukaemia, lymphoma and neuroblastoma, autoimmune disorders such as
CC multiple sclerosis, connective tissue disease, rheumatoid arthritis,
CC diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
CC disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
CC chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
CC Wernicke disease, inflammatory disorders such as nephritis, Crohn's
CC disease, ischaemia-reperfusion injury, shock, sepsis and inflammatory
CC bowel disease. The sequences exhibit activity relating to angiogenesis,
CC cell proliferation, cell differentiation, stem cell growth factor,
CC activin or inhibin. Therefore, they can be used to manipulate stem cells
CC in culture to give rise to neuroepithelial cells that can be used to
CC augment or replace cells damaged by illness, accidental damage or genetic
CC disorders. The sequences may also be used for regeneration of bone,
CC cartilage, tendons and ligaments and in tissue repair and burn healing.
CC Note: Some sequences for this patent did not form part of the printed
CC specification, but were obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 146 AA;

Alignment Scores:

Pred. No.:	1.5e-34	Length:	146
Score:	43.00	Matches:	43
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	8.50%	Indels:	0
DB:	22	Gaps:	0

US-09-745-506-74 (1-1553) x AAU27916 (1-146)

```
Qy        257 GCTCTCCTTTCTTCCTTGAATGACTTTGCATCCCTCTCGTTTGCTGAGAGTTGGGACAAT 316
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         36 AlaLeuLeuSerSerLeuAsnAspPheAlaSerLeuSerPheAlaGluSerTrpAspAsn 55

Qy        317 GTTGGATTACTGGTGGAACCAAGCCCACCACATACTGTAAATACACTCTTCCTGACCAAT 376
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         56 ValGlyLeuLeuValGluProSerProProHisThrValAsnThrLeuPheLeuThrAsn 75

Qy        377 GACCTGACT 385
              |||||||||
Db         76 AspLeuThr 78
```

Search completed: August 22, 2003, 14:32:24
Job time : 112 secs